4 terminated, 1 approved for marketing, 1 completed. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow this drug Literature Review of L-melphalanyl-p-L-fluorophenylalanine ethyl ester trials Research Report on L-melphalanyl-p-L-fluorophenylalanine ethyl ester
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 54 | 2020-12-21 | 2023-06-08 |
| PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function Melflufen, Dexamethasone - Renal Impairment, Multiple Myeloma | Phase 2 | Terminated | Oncopeptides AB | 35 | 2018-08-28 | 2023-03-10 |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Oncopeptides AB | 56 | 2018-04-12 | 2022-12-19 |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide Melflufen, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 495 | 2017-06-12 | 2024-01-30 |
| A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Melphalan flufenamide (Melflufen), Dexamethasone - Multiple Myeloma | Phase 2 | Completed | Oncopeptides AB | 157 | 2016-12-28 | 2022-11-22 |
| Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma Melphalan Flufenamide, Dexamethasone - Relapsed and/or Refractory Multiple Myeloma | Approved for marketing | Oncopeptides AB | 2021-03-18 |
Multiple Myeloma (5) · Renal Insufficiency (1)
Oncopeptides AB (6)
Czechia (4) · Spain (4) · United States (4) · France (3) · Greece (3) · Poland (3) · Italy (2) · Norway (2) · Russia (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Denmark (1) · Estonia (1) · Georgia (1)
Johan Harmenberg, MD, PhD (1) · Pieter Sonneveld, Prof. (1)
PMID 37355418, PMID 33296242, PMID 34671975, PMID 35032434, PMID 37646657, PMID 37646660, PMID 38426292, PMID 41437395
2018 (1), 2019 (1)